Agenus Appoints Evan Ballantyne As CFO

(RTTNews) - Agenus Inc. (AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced that it has appointed Evan Ballantyne as its Chief Financial Officer or CFO, effective immediately. Ballantyne will be responsible for all aspects of the company's financial, accounting, investor relations and corporate communication functions.

In connection with Ballantyne's appointment, Agenus granted Ballantyne an inducement equity award in accordance with NASDAQ Listing Rule 5635(c)(4). This award, which is outside of Agenus' 2009 Equity Incentive Plan, was approved by Agenus' board of directors, including all of its independent directors, as an inducement material to Mr. Ballantyne entering into employment with the Company.